Ablation, Lenvatinib, Local Therapy, Recurrent Hepatocellular Carcinoma, Systemic Therapy
Conditions
Keywords
Lenvatinb, Hepatocellular carcinoma, Microwave ablation, Radiofrequency ablation, Cryoablation
Brief summary
Studies have shown that combination therapy of TACE with Lenvatinib could achieve better survival outcomes than TACE alone for hepatocellular carcinoma (HCC) at BCLC B stage. However, whether patients could benefit from the ablation for intermediate recurrent HCC (RHCC) is still need high quality clinical evidence. This study is to evaluate the efficacy of ablation combined with TACE and Lenvatinib for the intermediate-stage RHCC.
Detailed description
The evidence of ablation combined transarterial chemoembolisation (TACE) and Lenvatinib for intermediate-stage recurrent hepatocellular carcinoma (RHCC) is limited. Patient responses to this treatment vary because of the heterogeneous nature of RHCC. Thus, it is important to identify patients who are most likely to benefit from this three regimes therapy. The aim of this study is to comparison of TACE-Lenvatinib with TACE-Lenvatinib-ablation for intermediate RHCC.
Interventions
PROCEDURETACE
TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.
PROCEDUREAblation
Ablation (radiofrequency ablation, microwave ablation, cryoablation), ablation followed TACE within 6-8 weeks and Lenvatinib continued. Percutaneous ablation was performed by ultrasound or CT. The ablation success is evaluated by achieving an ablative margin of 0.5 cm or more than the tumor size.
DRUGLenvatinb
Lenvatinb (12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day )
Sponsors
Chinese PLA General Hospital
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. 18-75 years; 2. RHCC diagnosed by imaging; 3. intermediate-stage RHCC (two to three lesions which at least one was \>3 cm in size or more than three tumors); 4. the tumor number was no more than six, and the maximum tumor diameter was ≤5 cm; 5. absence of extrahepatic metastasis or macrovascular invasion; 6. Child-Pugh class A or B; 7. TACE as initial treatment after tumor recurrence and showed no tumor progression after TACE. 8. life expectance \>3 months;
Exclusion criteria
1. under 18 years or over 75 years of age; 2. primary intermediate-stage HCC; 3. RHCC with more than six tumors, or single RHCC (5) RHCC \>5cm; (6) extrahepatic metastasis; (7) macrovascular tumor thrombus;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 24 months | PFS is defined as the time from the date of inclusion to the date of the first objectively documented tumor progression or death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival (OS) | 36 month | OS is the length of time from the date of inclusion until death from any cause. |
| Objective response rate (ORR) | 12 months | ORR, as determined based on tumor response according to mRECIST, is defined as partial response and complete response. |
Countries
China
Contacts
Primary ContactQunfang Zhou
Backup ContactFeng Duan
Outcome results
None listed